Moderate Certainty Evidence Suggests the Use of High-Flow Nasal Cannula Does Not Decrease Hypoxia When Compared With Conventional Oxygen Therapy in the Peri-Intubation Period: Results of a Systematic Review and Meta-Analysis.


Journal

Critical care medicine
ISSN: 1530-0293
Titre abrégé: Crit Care Med
Pays: United States
ID NLM: 0355501

Informations de publication

Date de publication:
04 2020
Historique:
entrez: 25 3 2020
pubmed: 25 3 2020
medline: 10 2 2021
Statut: ppublish

Résumé

The role of high-flow nasal cannula during and before intubation is unclear despite a number of randomized clinical trials. Our objective was to conduct a systematic review and meta-analysis examining the benefits of high-flow nasal cannula in the peri-intubation period. We performed a comprehensive search of relevant databases (MEDLINE, EMBASE, and Web of Science). We included randomized clinical trials that compared high-flow nasal cannula to other noninvasive oxygen delivery systems in the peri-intubation period. Our primary outcome was severe desaturation (defined as peripheral oxygen saturation reading < 80% during intubation). Secondary outcomes included peri-intubation complications, apneic time, PaO2 before and after intubation, PaCO2 after intubation, ICU length of stay, and short-term mortality. We included 10 randomized clinical trials (n = 1,017 patients). High-flow nasal cannula had no effect on the occurrence rate of peri-intubation hypoxemia (relative risk, 0.98; 95% CI, 0.68-1.42; 0.3% absolute risk reduction, moderate certainty), serious complications (relative risk, 0.87; 95% CI, 0.71-1.06), apneic time (mean difference, 10.3 s higher with high-flow nasal cannula; 95% CI, 11.0 s lower to 31.7 s higher), PaO2 measured after preoxygenation (mean difference, 3.6 mm Hg higher; 95% CI, 3.5 mm Hg lower to 10.7 mm Hg higher), or PaO2 measured after intubation (mean difference, 27.0 mm Hg higher; 95% CI, 13.2 mm Hg lower to 67.2 mm Hg higher), when compared with conventional oxygen therapy. There was also no effect on postintubation PaCO2, ICU length of stay, or 28-day mortality. We found moderate-to-low certainty evidence that the use of high-flow nasal cannula likely has no effect on severe desaturation, serious complications, apneic time, oxygenation, ICU length of stay, or overall survival when used in the peri-intubation period when compared with conventional oxygen therapy.

Identifiants

pubmed: 32205604
doi: 10.1097/CCM.0000000000004217
pii: 00003246-202004000-00016
doi:

Substances chimiques

Oxygen S88TT14065

Banques de données

ClinicalTrials.gov
['NCT02107183']

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

571-578

Auteurs

Dipayan Chaudhuri (D)

Department of Medicine, McMaster University, Hamilton, ON, Canada.

David Granton (D)

Department of Medicine, McMaster University, Hamilton, ON, Canada.

Dominic Xiang Wang (DX)

Schulich School of Medicine, Western University, London, ON, Canada.

Sharon Einav (S)

General Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Yigal Helviz (Y)

General Intensive Care Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

Tommaso Mauri (T)

Dipartimento di fisopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Milan, Italy.
Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Jean-Damien Ricard (JD)

Assistance Publique-Hôpital de Paris, Service de Réanimation Médico-chirurgicale, Hôpital Louis Mourier, Colombes, France.
Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, Paris, France.

Jordi Mancebo (J)

Servei de Medicina Intensiva, Hospital Universitari Sant Pau, Barcelona, Spain.

Jean-Pierre Frat (JP)

CHU de Poitiers, Médecine Intensive Réanimation, Poitiers, France.
INSERM, CIC-1402, équipe ALIVE, Poitiers, France.
Université de Poitiers, Faculté de Médecine et de Pharmacie de Poitiers, Poitiers, France.

Sameer Jog (S)

Department of Intensive Care Medicine, Deenanath Mangeshkar Hospital and Research Centre, Pune, India.

Gonzalo Hernandez (G)

Intensive Care Unit, Hospital Infanta Sofía, Madrid, Spain.

Salvatore M Maggiore (SM)

Department of Medical, Oral and Biotechnological Sciences, Gabriele d'Annunzio University of Chieti-Pescara, AND Department of Anesthesiology and Critical Care, SS. Annunziata Hospital, Chieti, Italy.

Carol Hodgson (C)

Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

Samir Jaber (S)

University Hospital of Montpellier and Saint Eloi Hospital, Montpellier University, Montpellier, France.

Laurent Brochard (L)

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.

Karen E A Burns (KEA)

Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, ON, Canada.

Bram Rochwerg (B)

Department of Medicine, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH